Note 2 - Revenues 10K

9 Months Ended

12 Months Ended

Sep. 30, 2020

Dec. 31, 2019

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

(

2

) REVENUES:

The Company operates in

one

business segment, which primarily focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. However, substantially all of the Company's revenues are derived from the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. Currently, a small portion of the Company's revenues are also generated by sales of Trappsol® Cyclo™ to South America (Brazil) for the treatment of NPC patients.

The Company considers there to be revenue concentration risks for regions where net product revenues exceed

10%

of consolidated net product revenues. The concentration of the Company's net product revenues within the regions below

may

have a material adverse effect on the Company's revenues and results of operations if sales in the respective regions experience difficulties.

Revenues by product are summarized as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		20 19
Trappsol ® Cyclo™	$	-	$	73,500	$	30,096	$	103,596
Trappsol ® HPB		92,384		152,784		458,934		359,530
Trappsol ® Fine Chemical		127,963		57,620		261,300		162,572
Aquaplex ®		-		-		928		149,690
Other		2,115		2,010		6,532		4,447
Total revenues	$	222,462	$	285,914	$	757,790	$	779,835

Substantially all of our sales of Trappsol

®

Cyclo™ for the

nine

months ended

September 30, 2020

and year ended

December 

31,

2019

were to a single customer who exports the drug to South America. All of our Aquaplex

®

sales for the

nine

months ended

September 30, 2020

and year ended

December 31, 2019

were to

three

customers.

(

2

) REVENUES:

The Company operates in

one

business segment, which primarily focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where net product revenues exceed

10%

of consolidated net product revenues. The concentration of the Company's net product revenues within the regions below

may

have a material adverse effect on the Company's revenues and results of operations if sales in the respective regions experience difficulties. The Company adopted the requirements of ASC

606

on

January 

1,

2018

using the modified retrospective method. See Note

1

(i) – Revenue Recognition for additional discussion.

Revenues by product are summarized as follows:

	Year Ended
	December 31,
	2019		2018
Trappsol ® Cyclo™	$	103,596	$	166,596
Trappsol ® HPB		481,379		484,101
Trappsol ® Fine Chemical		265,947		233,910
Aquaplex ®		149,878		116,806
Other		6,398		10,064
Total revenues	$	1,007,198	$	1,011,477

Substantially all of our sales of Trappsol

®

Cyclo™ for the years ended

December 31, 2019

and

2018

were to a single customer who exports the drug to South America. Substantially all of our Aquaplex

®

sales are to

one

customer.